2028267-73-2: Tofacitinib N-oxide impurity

Tofacitinib N oxide impurity (CAS No: 2028267-73-2) Or (3R,4R)-4-Methyl-3-(methyloxido-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-v-oxo-1-piperidinepropanenitrile, Tofacitinib N oxide is an impurity of Tofacitinib, Tofacitinib is a CYP3A4 substrate and a minor CYP2C19 substrate, used in the treatment of rheumatoid arthritis.

Additional information on CAS 2028267-73-2

Catalogue No.

VE008142

CAS No.

2028267-73-2

Molecular Formula

C16H20N6O2

Molecular Weight

328.38 g/mol

Parent drug

Tofacitinib

IUPAC Name

(3R, ​4R)​-4-​Methyl-​3-​(methyloxido-​7H-​pyrrolo[2, ​3-​d]​pyrimidin-​4-​ylamino)​-​β-​oxo-1-​piperidinepropanenit​rile

Synonyms

N/A

References

Sci-Hub, An Improved and Efficient Process for the Preparation of Tofacitinib Citrate, 10.1021/op500274j. (2014). Retrieved January 29, 2022, from Sci-hub.ee website: https://sci-hub.ee/10.1021/op500274j ?

Status

In-stock

[rfq_list]

Login first to add product to RFQ List

Request a quote

2028267-73-2: Tofacitinib N-oxide impurity

2028267-73-2: Tofacitinib N-oxide impurity
Catalogue No.

VE008142

CAS No.

2028267-73-2

Molecular Formula

C16H20N6O2

Molecular Weight

328.38 g/mol

Parent drug

Tofacitinib

IUPAC Name

(3R, ​4R)​-4-​Methyl-​3-​(methyloxido-​7H-​pyrrolo[2, ​3-​d]​pyrimidin-​4-​ylamino)​-​β-​oxo-1-​piperidinepropanenit​rile

Synonyms

N/A

References

Sci-Hub, An Improved and Efficient Process for the Preparation of Tofacitinib Citrate, 10.1021/op500274j. (2014). Retrieved January 29, 2022, from Sci-hub.ee website: https://sci-hub.ee/10.1021/op500274j ?

Status

In-stock

ListName

Tofacitinib N-oxide impurity

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden